IWIrene Watpool

Irene Watpool

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Irene Watpool has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Monitoring and auditing protocol adherence, data integrity and ethical conduct of a randomized clinical trial: A case study

    by Alyson Takaoka, Nicole Zytaruk, Megan Davis, Andrea Matte, Jennie Johnstone, François Lauzier, John Marshall, Neill Adhikari, France J. Clarke, Bram Rochwerg, et al.


  • Open Access

    Lessening Organ dysfunction with VITamin C (LOVIT): protocol for a randomized controlled trial

    by on behalf of the Canadian Critical Care Trials Group, Marie-Hélène Masse, Julie Ménard, Sheila Sprague, Marie-Claude Battista, Deborah J. Cook, Gordon H. Guyatt, Daren K. Heyland, Salmaan Kanji, Ruxandra Pinto, et al.

    Background: Sepsis is a health problem of global importance; treatments focus on controlling infection and supporting failing organs. Recent clinical research suggests that intravenous vitamin C may decrease mortality in sepsis. We have designed a randomized controlled trial (RCT) to ascertain the effect of vitamin C on the composite endpoint of death or persistent organ dysfunction at 28 days in patients with sepsis. Methods: LOVIT (Lessening Organ dysfunction with VITamin C) is a multicenter, parallel-group, blinded (participants, clinicians, study personnel, Steering Committee members, data analysts), superiority RCT (minimum n = 800). Eligible patients have sepsis as the diagnosis for admission to the intensive care unit (ICU) and are receiving vasopressors. Those admitted to the ICU for more than 24 h are excluded. Eligible patients are randomized to high-dose intravenous vitamin C (50 mg/kg every 6 h for 96 h) or placebo. The primary outcome is a composite of death or persistent organ dysfunction (need for vasopressors, invasive mechanical ventilation, or new and persisting renal replacement therapy) at day 28. Secondary outcomes include persistent organ dysfunction-free days to day 28, mortality and health-related quality of life at 6 months, biomarkers of dysoxia, inflammation, infection, endothelial function, and adverse effects (hemolysis, acute kidney injury, and hypoglycemia). Six subgroup analyses are planned. Discussion: This RCT will provide evidence of the effect of high-dose intravenous vitamin C on patient-important outcomes in patients with sepsis. Trial registration: clinicaltrials.gov, NCT03680274, first posted 21 September 2018.


  • Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial

    by Lauralyn A. McIntyre, Duncan J. Stewart, Shirley H. J. Mei, David Courtman, Irene Watpool, John Granton, John Marshall, Claudia dos Santos, Keith R. Walley, Brent W. Winston, et al.

    Rationale: In septic animal models mesenchymal stem (stromal) cells (MSCs) modulate inflammation, enhance tissue repair and pathogen clearance, and reduce death. Objectives: To conduct a phase I dose escalation trial of MSCs in septic shock with the primary objective of examining the safety and tolerability of MSCs. Methods: We enrolled nine participants within 24 hours of admission to the ICU. A control cohort of 21 participants was enrolled before starting the MSC interventional cohort to characterize expected adverse events (AEs) and to serve as a comparator for the intervention cohort. Three separate MSC dose cohorts, with three participants per cohort, received a single intravenous dose of 0.3, 1.0, and 3.0 × 106 cells/kg. A prespecified safety plan monitored participants for the occurrence of AEs; cytokines were collected at prespecified time points. Measurements and Main Results: Ages of participants in the interventional versus observational cohorts were median of 71 (range, 38–91) and 61 (range, 23–95). Acute Physiology and Chronic Health Evaluation scores were median of 25 (range, 11–28) and 26 (range, 17–32). MSC doses ranged from 19 to 250 million cells. There were no prespecified MSC infusion–associated or serious unexpected AEs, nor any safety or efficacy signals for the expected AEs or the measured cytokines between the interventional and observational cohorts. Conclusions: The infusion of freshly cultured allogenic bone marrow–derived MSCs, up to a dose of 3 million cells/kg (250 million cells), into participants with septic shock seems safe. Clinical trial registered with www.clinicaltrials.gov (NCT02421484).